- Conditions
- Fuchs Endothelial Corneal Dystrophy
- Interventions
- Ripasudil, Placebo
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Palo Alto, California • Sacramento, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Corneal Edema After Cataract Surgery
- Interventions
- Ripasudil, Placebo
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Hemet, California + 37 more
- Conditions
- Fuchs Endothelial Dystrophy
- Interventions
- Glanatec, Optive, Ophthalmic Solution, Descemet Membrane Endothelial Keratoplasty
- Drug · Procedure
- Lead sponsor
- Michael D. Straiko, MD
- Other
- Eligibility
- 30 Years to 99 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Fuchs
- Interventions
- Topical Ripasudil, Topical Placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Palo Alto, California • Sacramento, California • Palm Beach Gardens, Florida + 3 more
- Conditions
- Fuchs Endothelial Corneal Dystrophy
- Interventions
- Ripasudil, Placebo
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 21
- States / cities
- Los Angeles, California • Palo Alto, California • Sacramento, California + 17 more
- Conditions
- Fuchs' Endothelial Dystrophy
- Interventions
- Ripasudil hydrochloride hydrate 0.4% ophthalmic solution
- Drug
- Lead sponsor
- Marian Macsai, MD
- Other
- Eligibility
- 18 Years to 91 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Glenview, Illinois
- Conditions
- Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy
- Interventions
- Ripasudil, Placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 8
- States / cities
- Palo Alto, California • Sacramento, California • Palm Beach Gardens, Florida + 3 more